<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">8912548</article-id><article-id pub-id-type="pmc">2074772</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rustin</surname><given-names>G. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Quinnell</surname><given-names>T. G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Clarke</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nelstrop</surname><given-names>A. E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bollag</surname><given-names>W.</given-names></name></contrib></contrib-group><aff>Department of Medical Oncology, Mount Vernon Centre for Cancer Treatment, Mount Vernon Hospital, Northwood, Middlesex, UK.</aff><pub-date pub-type="ppub"><month>11</month><year>1996</year></pub-date><volume>74</volume><issue>9</issue><fpage>1479</fpage><lpage>1481</lpage><abstract><p>Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00025-0155.tif" xlink:title="scanned-page" xlink:role="1479" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00025-0156.tif" xlink:title="scanned-page" xlink:role="1480" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00025-0157.tif" xlink:title="scanned-page" xlink:role="1481" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

